Mealey's (April 24, 2020, 10:34 AM EDT) -- WASHINGTON, D.C. — Novartis prevailed April 23 when the Federal Circuit U.S. Court of Appeals found that a dissatisfied inter partes review (IPR) petitioner lacks standing to appeal a final written decision by the Patent Trial and Appeal Board that confirmed the patentability of a challenged method for treating relapsing-remitting multiple sclerosis (RR-MS) (Argentum Pharmaceuticals LLC v. Novartis Pharmaceuticals Corporation, No. 18-2273, Fed. Cir., 2020 U.S. App. LEXIS 13034)....